Bicycle Therapeutics (BCYC) Receivables - Other (2019 - 2026)

Bicycle Therapeutics (BCYC) has 8 years of Receivables - Other data on file, last reported at $47.4 million in Q2 2026.

• Quarterly Receivables - Other fell 22.01% year-over-year to $47.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $47.4 million (down 22.01% YoY) and the FY2025 annual result came in at $35.6 million, changed 0.28% from the prior year.
• Receivables - Other advanced to $47.4 million in Q2 2026, from $40.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $67.3 million in Q3 2025 to a low of $11.4 million in Q3 2022.
• A 5-year average of $34.4 million and a median of $35.6 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other jumped 260.47% — and 2026, when it dropped 22.01%.
• Tracing BCYC's Receivables - Other over 5 years: stood at $19.2 million in 2022, then climbed by 25.45% to $24.0 million in 2023, then jumped by 48.51% to $35.7 million in 2024, then declined by 0.28% to $35.6 million in 2025, then surged by 33.2% to $47.4 million in 2026.
• The last three Receivables - Other figures came in at $47.4 million (Q2 2026), $40.9 million (Q1 2026), and $35.6 million (Q4 2025), per Business Quant data.